Multiple peripheral odontogenic fibroma, world health organization type, and central giant cell granuloma: A case report of an unusual association

Central giant cell granuloma (central giant cell granuloma) is an uncommon benign bony lesion that occurs in the mandible and maxilla and accounts for approximately 7% of all benign tumours of the jaws [1]. The World Health Organization (WHO) has defined central giant cell granuloma as an intraosseous lesion consisting of cellular fibrous tissue that contains multiple foci of haemorrhage, aggregations of multinucleated giant cells and occasional trabeculae of woven bone [2]. Central giant cell granuloma occurs predominantly in children or young adults, with approximately 75%of cases presenting before 30 years of age although presentation can occur at any age [3]. Females are affected more frequently than males, with a ratio of 2:1

Download Full-text

Hybrid Central Odontogenic Fibroma with Central Giant Cell Granuloma Like Lesion ; A Case Report and Review of the Literature

Siriraj Medical Journal ◽

10.33192/smj.2019.63 ◽

2019 ◽

Vol 71 (5) ◽

pp. 426-431 ◽

Cited By ~ 1

Author(s):

Sakanus Vijintanawan

Keyword(s):

Case Report ◽

Giant Cell ◽

Giant Cell Granuloma ◽

Review Of The Literature ◽

Central Giant Cell Granuloma ◽

Odontogenic Fibroma ◽

Central Odontogenic Fibroma

Download Full-text

Extensive Aggressive Central Giant Cell Granuloma of the Mandible: Conservative Steroids Treatment in a Pediatric Patient

Craniomaxillofacial Trauma & Reconstruction Open ◽

10.1055/s-0037-1601482 ◽

2017 ◽

Vol 1 (1) ◽

pp. s-0037-1601482

Author(s):

Pietro Boni ◽

Alberto Bozzetti ◽

Valeria Morganti ◽

Giorgio Novelli ◽

Davide Sozzi

Keyword(s):

Giant Cell ◽

Pediatric Patient ◽

Corticosteroid Injection ◽

Fibrous Tissue ◽

Treatment Protocol ◽

World Health ◽

Giant Cell Granuloma ◽

Central Giant Cell Granuloma ◽

Intralesional Corticosteroid ◽

Health Organization

Central giant cell granuloma (CGCG) is a relatively rare intraosseous lesion, described by the World Health Organization as a localized proliferation consisting of fibrous tissue with hemorrhage deposits, the presence of osteoclast-like cells, and reactive bone formation. In this article, the authors present their experience in managing a wide, aggressive CGCG of the whole tooth-bearing mandible in a 9-year-old pediatric patient. The extension of the lesion and the age of the patient have presented a double challenge concerning treatment and outcome. If fact the main objective remains a correct therapeutic treatment, focused on healing the patient and avoiding recurrences, the clinician must be careful in preventing an excessive morbidity. The authors decided to treat the young patient with intralesional corticosteroid therapy, reserving surgery in case of non-response or for subsequent refinements. In this article is presented the authors’ conservative treatment protocol with intralesional corticosteroid injection and their results are compared with literature's data.

Download Full-text

Hybrid central odontogenic fibroma and central giant cell granuloma lesion – A case report of an aggressive and recurrent lesion

Journal of Oral and Maxillofacial Surgery Medicine and Pathology ◽

10.1016/j.ajoms.2019.08.003 ◽

2019 ◽

Vol 31 (6) ◽

pp. 432-434 ◽

Cited By ~ 1

Author(s):

Andres Flores-Hidalgo ◽

Teresa Biggerstaff ◽

Valerie Murrah

Keyword(s):

Case Report ◽

Giant Cell ◽

Giant Cell Granuloma ◽

Central Giant Cell Granuloma ◽

Recurrent Lesion ◽

Odontogenic Fibroma ◽

Central Odontogenic Fibroma

Download Full-text

A Case of Polyneuropathy Following a Single Dose of Diethylcarbamazine and Albendazole During Mass Administration of Drug - A Case Report

Nepal Journal of Medical Sciences ◽

10.3126/njms.v1i1.5800 ◽

1970 ◽

Vol 1 (1) ◽

pp. 56-58

Author(s):

SC Kohli ◽

UK Shrestha ◽

VM Alurkar ◽

A Maskey ◽

M Parajuli ◽

...

Keyword(s):

Abdominal Pain ◽

Single Dose ◽

Case Report ◽

Side Effects ◽

World Health Organization ◽

Mass Drug Administration ◽

World Health ◽

Medical Sciences ◽

The World ◽

Health Organization

The global program to eliminate Lymphatic Filariasis created by The World Health organization in 1997 is based on mass administration of single annual doses of diethylcarbamazine ( DEC) plus albendazole in non African regions and of albendazole plus ivermectin in Africa. The usual side effects of DEC treatment include fever, chills, arthralgia, headaches, nausea, and vomiting. Albendazole is associated with relatively few side effects consisting of occasional nausea, vomiting, abdominal pain, headache, reversible alopecia, elevated aminotransferases and rarely leucopenia and rash. We report a case of polyneuropathy in a young individual following DEC and albendazole during mass drug administration. Keywords: Albendazole; DEC; Polyneuropathy. DOI: http://dx.doi.org/10.3126/njms.v1i1.5800 Nepal Journal of Medical Sciences. 2012; 1(1): 56-58

Download Full-text